42 U.S.C. § 285a–7 — Prostate cancer

submitted 82 years ago by Pub. L. 103-43 to r/title-42-THE-PUBLIC-HEALTH-AND-WELFARE · 579 words · no verdicts yet

in plain englishAI-generated · not legal advice

The Institute's Director must expand and coordinate prostate cancer research, working with other NIH institutes. This covers basic and clinical research, PSA-based early detection, an inter-institute task force, control programs, education, and at least six research centers. All of this must follow a written plan sent to Congress and other officials.

(a) Expansion and coordination of activities. The Director, after consulting the National Cancer Advisory Board, must expand, intensify, and coordinate the Institute's prostate cancer research. (b) Coordination with other institutes. The Director must coordinate this with similar work by other national research institutes and NIH agencies that deal with prostate cancer. (c) Programs. (1) The Director must research, or support research on, understanding and curing prostate cancer, expanding and intensifying: (A) basic research on its causes; (B) clinical research on preventing, detecting, and treating it; (C) prevention, control, and early-detection programs under section 285a–1, especially research on using prostate-specific antigen (PSA) to screen for and catch prostate cancer early; (D) an Inter-Institute Task Force, led by the Director, to coordinate NIH's prostate cancer research efforts; (E) control programs under section 285a–1; (F) information and education programs under section 285a–2; and (G) research and demonstration centers under section 285a–3, including centers that bring together basic, clinical, biomedical, and behavioral scientists to study prostate cancer. At least six such centers must operate. These centers should support new researchers and training programs, and must prioritize moving research advances into clinical use quickly. (2) Implementation of plan for programs. (A) The Director must make sure these programs follow a written plan, which may include the Director's own comments and recommendations, giving weight to the Institute's professional judgment as reflected in its annual budget estimate. The Director, with the Advisory Board, must periodically review and update this plan. (B) By October 1, 1993, the Director had to send the plan to the President's Cancer Panel, the Secretary, and the Director of NIH. (C) The Director must send any updates to those same three. (D) The Secretary must give the plan and any updates to the House Energy and Commerce Committee and the Senate Labor and Human Resources Committee.

the actual law source: uscode.house.gov ↗public domain

(a) Expansion and coordination of activities

The Director of the Institute, in consultation with the National Cancer Advisory Board, shall expand, intensify, and coordinate the activities of the Institute with respect to research on prostate cancer.

(b) Coordination with other institutes

The Director of the Institute shall coordinate the activities of the Director under subsection (a) with similar activities conducted by other national research institutes and agencies of the National Institutes of Health to the extent that such Institutes 1 and agencies have responsibilities that are related to prostate cancer.

(1) In general

In carrying out subsection (a), the Director of the Institute shall conduct or support research to expand the understanding of the cause of, and to find a cure for, prostate cancer. Activities under such subsection shall provide for an expansion and intensification of the conduct and support of—

(A)

basic research concerning the etiology and causes of prostate cancer;

(B)

clinical research and related activities concerning the causes, prevention, detection and treatment of prostate cancer;

(C)

prevention and control and early detection programs with respect to prostate cancer in accordance with section 285a–1 of this title, particularly as it relates to intensifying research on the role of prostate specific antigen for the screening and early detection of prostate cancer;

(D)

an Inter-Institute Task Force, under the direction of the Director of the Institute, to provide coordination between relevant National Institutes of Health components of research efforts on prostate cancer;

(E)

control programs with respect to prostate cancer in accordance with section 285a–1 of this title;

(F)

information and education programs with respect to prostate cancer in accordance with section 285a–2 of this title; and

(G)

research and demonstration centers with respect to prostate cancer in accordance with section 285a–3 of this title, including the development and operation of centers for prostate cancer research to bring together basic and clinical, biomedical and behavioral scientists to conduct basic, clinical, epidemiological, psychosocial, prevention and control, treatment, research, and related activities on prostate cancer.

Not less than six centers shall be operated under subparagraph (G). Activities of such centers should include supporting new and innovative research and training programs for new researchers. Such centers shall give priority to expediting the transfer of research advances to clinical applications.

(2) Implementation of plan for programs

(A)

The Director of the Institute shall ensure that the research programs described in paragraph (1) are implemented in accordance with a plan for the programs. Such plan shall include comments and recommendations that the Director of the Institute considers appropriate, with due consideration provided to the professional judgment needs of the Institute as expressed in the annual budget estimate prepared in accordance with section 285a–2(9) 2 of this title. The Director of the Institute, in consultation with the National Cancer Advisory Board, shall periodically review and revise such plan.

(B)

Not later than October 1, 1993, the Director of the Institute shall submit a copy of the plan to the President’s Cancer Panel, the Secretary, and the Director of NIH.

(C)

The Director of the Institute shall submit any revisions of the plan to the President’s Cancer Panel, the Secretary, and the Director of NIH.

(D)

The Secretary shall provide a copy of the plan submitted under subparagraph (A), and any revisions submitted under subparagraph (C), to the Committee on Energy and Commerce of the House of Representatives and the Committee on Labor and Human Resources of the Senate.

Source credit: (July 1, 1944, ch. 373, title IV, § 417A, as added Pub. L. 103–43, title IV, § 402, June 10, 1993, 107 Stat. 155.)

history & why it existsrecord from the source credit

1944Enacted · Pub. L. 103-43 · 107 Stat. 155

A history note hasn’t been published yet. The record shows enactment by Pub. L. 103-43 on 1944-07-01.

all 0 arguments · sorted by: best

no arguments yet — make the first case